DEA Policy Safety Therapy 
Cannabis Law Report
DECEMBER 7, 2021
On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.
Veriheal
JUNE 30, 2023
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. The document also addresses study participant safety emphasizing how psychedelics’ psychoactive effects increase the potential for abuse.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. DEA and the Controlled Substances Act.
Veriheal
AUGUST 24, 2022
This campaign was backed by New Approach PAC, a nationwide political organization that is focused on supporting progressive reform surrounding cannabis and criminal justice policies. In May 2022, Connecticut’s governor signed a budget bill that included a provision for the implementation of psychedelic-assisted therapy treatment centers.
Cannabis Law Report
FEBRUARY 28, 2022
Moreover, because Indigenous communities pioneered many aspects of modern psychedelic therapies, their patenting by Western corporations may promote biopiracy, the exploitation of Indigenous knowledge without compensation. MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study , 27 NATURE MED.
Cannabis Law Report
AUGUST 23, 2021
Abernethy said, “We [FDA] remain focused on exploring potential pathways for CBD products to be lawfully marketed while also educating the public about these outstanding questions of CBD’s safety.”. He added that significant data is still needed to inform policy regarding use of consumer cannabis products.
CannaMD
SEPTEMBER 10, 2020
Is it safe to continue cannabis-based therapies during pregnancy? This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented.
Expert insights. Personalized for you.
52 
Let's personalize your content